Cyclophilin A is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance in Vitro

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2008 Apr 4

PMID 18385230

Citations 123

Authors

Feng Yang

Jason M Robotham

Heather B Nelson

Andre Irsigler

Rachael Kenworthy

Hengli Tang

Affiliations

Soon will be listed here.

Abstract

Cyclosporine (CsA) and its derivatives potently suppress hepatitis C virus (HCV) replication. Recently, CsA-resistant HCV replicons have been identified in vitro. We examined the dependence of the wild-type and CsA-resistant replicons on various cyclophilins for replication. A strong correlation between CsA resistance and reduced dependency on cyclophilin A (CyPA) for replication was identified. Silencing of CyPB or CyPC expression had no significant effect on replication, whereas various forms of small interfering RNA (siRNA) directed at CyPA inhibited HCV replication of wild-type but not CsA-resistant replicons. The efficiency of a particular siRNA in suppressing CyPA expression was correlated with its potency in inhibiting HCV replication, and expression of an siRNA-resistant CyPA cDNA rescued replication. In addition, an anti-CyPA antibody blocked replication of the wild-type but not the resistant replicon in an in vitro replication assay. Depletion of CyPA alone in the CsA-resistant replicon cells eliminated CsA resistance, indicating that CyPA is the chief mediator of the observed CsA resistance. The dependency on CyPA for replication was observed for both genotype (GT) 1a and 1b replicons as well as a GT 2a infectious virus. An interaction between CyPA and HCV RNA as well as the viral polymerase that is sensitive to CsA treatment in wild-type but not in resistant replicons was detected. These findings reveal the molecular mechanism of CsA resistance and identify CyPA as a critical cellular cofactor for HCV replication and infection.

Citing Articles

Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV.

Newton L, Gathmann C, Ridewood S, Smith R, Wijaya A, Hornsby T Nat Commun. 2025; 16(1):1484.

PMID: 39929804 PMC: 11811207. DOI: 10.1038/s41467-025-56317-8.

Exploration of the Role of Cyclophilins in Established Hepatitis B and C Infections.

Molle J, Duponchel S, Rieusset J, Ovize M, Ivanov A, Zoulim F Viruses. 2025; 17(1.

PMID: 39861799 PMC: 11768883. DOI: 10.3390/v17010011.

Targeting NTCP for liver disease treatment: A promising strategy.

Tan X, Xiang Y, Shi J, Chen L, Yu D J Pharm Anal. 2024; 14(9):100979.

PMID: 39310850 PMC: 11415714. DOI: 10.1016/j.jpha.2024.100979.

Cyclophilin inhibition as a strategy for the treatment of human disease.

Stauffer W, Goodman A, Gallay P Front Pharmacol. 2024; 15:1417945.

PMID: 39045055 PMC: 11264201. DOI: 10.3389/fphar.2024.1417945.

Marmosets as models of infectious diseases.

Herron I, Laws T, Nelson M Front Cell Infect Microbiol. 2024; 14:1340017.

PMID: 38465237 PMC: 10921895. DOI: 10.3389/fcimb.2024.1340017.

References

Gamble T, Vajdos F, Yoo S, Worthylake D, Houseweart M, Sundquist W . Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell. 1996; 87(7):1285-94. DOI: 10.1016/s0092-8674(00)81823-1. View

Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y . Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005; 129(3):1031-41. DOI: 10.1053/j.gastro.2005.06.031. View

Munro S, Pelham H . An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell. 1986; 46(2):291-300. DOI: 10.1016/0092-8674(86)90746-4. View

Wang C, Gale Jr M, Keller B, Huang H, Brown M, Goldstein J . Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell. 2005; 18(4):425-34. DOI: 10.1016/j.molcel.2005.04.004. View

Zhao Y, Chen Y, Schutkowski M, Fischer G, Ke H . Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity. Structure. 1997; 5(1):139-46. DOI: 10.1016/s0969-2126(97)00172-x. View

Cai Z, Zhang C, Chang K, Jiang J, Ahn B, Wakita T . Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol. 2005; 79(22):13963-73. PMC: 1280219. DOI: 10.1128/JVI.79.22.13963-13973.2005. View

Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y . Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005; 19(1):111-22. DOI: 10.1016/j.molcel.2005.05.014. View

Waninger S, Kuhen K, Hu X, Chatterton J, Wong-Staal F, Tang H . Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach. J Virol. 2004; 78(23):12829-37. PMC: 524980. DOI: 10.1128/JVI.78.23.12829-12837.2004. View

Ma S, Boerner J, TiongYip C, Weidmann B, Ryder N, Cooreman M . NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother. 2006; 50(9):2976-82. PMC: 1563518. DOI: 10.1128/AAC.00310-06. View

10.

Lindenbach B, Evans M, Syder A, Wolk B, Tellinghuisen T, Liu C . Complete replication of hepatitis C virus in cell culture. Science. 2005; 309(5734):623-6. DOI: 10.1126/science.1114016. View

11.

Yi M, Villanueva R, Thomas D, Wakita T, Lemon S . Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A. 2006; 103(7):2310-5. PMC: 1413728. DOI: 10.1073/pnas.0510727103. View

12.

Neri P, Gemmecker G, Zydowsky L, WALSH C, Fesik S . NMR studies of [U-13C]cyclosporin A bound to human cyclophilin B. FEBS Lett. 1991; 290(1-2):195-9. DOI: 10.1016/0014-5793(91)81258-a. View

13.

Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z . Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005; 11(7):791-6. PMC: 2918402. DOI: 10.1038/nm1268. View

14.

Handschumacher R, Harding M, Rice J, Drugge R, Speicher D . Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984; 226(4674):544-7. DOI: 10.1126/science.6238408. View

15.

Lindenbach B, Rice C . Unravelling hepatitis C virus replication from genome to function. Nature. 2005; 436(7053):933-8. DOI: 10.1038/nature04077. View

16.

Moradpour D, Evans M, Gosert R, Yuan Z, Blum H, Goff S . Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol. 2004; 78(14):7400-9. PMC: 434129. DOI: 10.1128/JVI.78.14.7400-7409.2004. View

17.

Sayah D, Sokolskaja E, Berthoux L, Luban J . Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature. 2004; 430(6999):569-73. DOI: 10.1038/nature02777. View

18.

Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T . Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J. 2006; 25(20):5015-25. PMC: 1618089. DOI: 10.1038/sj.emboj.7601367. View

19.

Hamamoto I, Nishimura Y, Okamoto T, Aizaki H, Liu M, Mori Y . Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J Virol. 2005; 79(21):13473-82. PMC: 1262604. DOI: 10.1128/JVI.79.21.13473-13482.2005. View

20.

Evans M, Rice C, Goff S . Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci U S A. 2004; 101(35):13038-43. PMC: 516513. DOI: 10.1073/pnas.0405152101. View